scholarly journals Effect of Ca2+, cyclic GMP, and cyclic AMP added to artificial solution perfusing lingual artery on frog gustatory nerve responses.

1982 ◽  
Vol 80 (5) ◽  
pp. 785-800 ◽  
Author(s):  
S Nagahama ◽  
Y Kobatake ◽  
K Kurihara
Keyword(s):  
Taste Cell ◽  
Lingual Artery ◽  
Channel Blockers ◽  
Ca Channel ◽  
Gustatory Nerve ◽  
Ca Channel Blockers ◽  
Chemical Stimuli ◽  
Group 2 ◽  
Artificial Solution ◽  
Group 1

The lingual artery of the bullfrog was perfused with artificial solution and the effects of Ca2+, Ca-channel blockers (MnCl2 and verapamil), cGMP, and cAMP added to the perfusing solution of the gustatory nerve responses were examined. The responses to chemical stimuli of group 1 (CaCl2, NaCl, distilled water, D-galactose, and L-threonine) applied to the tongue surface were greatly decreased by a decrease in Ca2+ concentration in the perfusing solution, suppressed by the Ca-channel blockers, enhanced by cGMP, and suppressed by cAMP. The responses to chemical stimuli of group 2 (quinine hydrochloride, theophylline, ethanol, and HCl) were practically not affected by a decrease in Ca2+ concentration, the Ca-channel blockers, cGMP, and cAMP. The responses to the stimuli of group 1 seem to be induced by Ca influx into a taste cell that is triggered by depolarization and modulated by the cyclic nucleotides in a taste cell. The responses to group 2 seem to be induced without accompanying Ca influx.

Abstract P024: Pharmacological Treatment of Hypertension and Lv Dysfunction Predictors in ESRD Patients With AV Fistula

Hypertension ◽  
2015 ◽  
Vol 66 (suppl_1) ◽  
Author(s):  
Sayed Tariq ◽  
James Anderson ◽  
Rohit Dhingra ◽  
Mikhail Torosoff
Keyword(s):  
Systolic Function ◽  
Beta Blockers ◽  
Systolic Dysfunction ◽  
Left Ventricular ◽  
Channel Blockers ◽  
Ca Channel ◽  
Av Fistula ◽  
Fistula Surgery ◽  
Lv Dysfunction ◽  
Ca Channel Blockers

Background: Effects of anti-hypertensive medications on left ventricular dimensions and systolic function in patients with arterio-venous (AV) fistulas have not been well investigated. Material and Methods: Medical charts and echocardiograms of 346 patients with AV fistula were reviewed. Of 346, 149 patients had TTE prior to the AV fistula surgery, 197 had TTE after the AV fistula surgery, and 76 patients had TTE before and after the AV fistula surgery. Data on medication use was available in 314 patients. ANOVA, chi-square, and logistic regression tests were employed. Results: In patients scheduled for AV fistula placement, 20% (31/149) patients had systolic dysfunction and 15% (22/142) had increased LV end-diastolic dimensions (LVEDD). Moderate systolic LV dysfunction was observed in 6% (9/149) and additional 8% (12/149) had severe LV dysfunction. Increased LVEDD with some LV dysfunction was noted in 27% (38/142).Following the AV fistula placement, 18% (36/197) of patients had systolic dysfunction and 12% (22/187) had increased LV end-diastolic dimensions (LVEDD). Moderate or severe systolic LV dysfunction was observed in 6% (5/197). LV systolic dysfunction or dilatation was noted in 23% (43/187). Of 314 patients, 63% were on beta-blockers (BB), 25% were on ACE inhibitor or an ARB , 43% on calcium-channel blocker , and 15% on alpha-antagonist . BB, ACEi-ARB, or AA were not associated with increased LVEDD or systolic dysfunction before or after the AV fistula placement. Prior to AV fistula, CCB treatment was not related to LV dilatation (36% in each group, p=0.981) Post AV fistula, CCB treatment was associated with increased LV dimensions (71% vs. 46%, p=0.029) but not LV systolic dysfunction (49% in LV dysfunction vs. 38% in the rest, p=0.446) . This association persisted after adjustment for co-morbidities and demographic parameters. Conclusions: LV systolic dysfunction and/or dilatation are common in patients undergoing AV fistula surgery. Despite decreased use of Ca-channel blockers in patients with LV dysfunction prior to AV fistula, Ca-channel blockers are associated with increased LV dimensions post AV fistula, and probably should be avoided in this vulnerable patient population.

Modulation of Adhesion Molecule Expression on Endothelial Cells by Verapamil and Other Ca++ Channel Blockers

Immunobiology ◽  
1994 ◽  
Vol 191 (1) ◽  
pp. 38-51 ◽  
Author(s):  
Nils P. Hailer ◽  
Roman A. Blaheta ◽  
Sebastian Harder ◽  
Martin Scholz ◽  
Albrecht Encke ◽  
...  
Keyword(s):  
Endothelial Cells ◽  
Adhesion Molecule ◽  
Channel Blockers ◽  
Ca Channel ◽  
Adhesion Molecule Expression ◽  
Ca Channel Blockers

An Assessment of the Oral Bioavailability of Three Ca-Channel Blockers Using a Cassette-Microdose Study: A New Strategy for Streamlining Oral Drug Development

2015 ◽  
Vol 104 (9) ◽  
pp. 3154-3161 ◽  
Author(s):  
Shinji Yamashita ◽  
Makoto Kataoka ◽  
Yuki Suzaki ◽  
Hiromitsu Imai ◽  
Takuya Morimoto ◽  
...  
Keyword(s):  
Drug Development ◽  
Oral Bioavailability ◽  
Oral Drug ◽  
Channel Blockers ◽  
Ca Channel ◽  
Ca Channel Blockers ◽  
New Strategy ◽  
Microdose Study

2-Alkyl-3-Alkylamino-2H-Benzo- and Pyridothiadiazine 1,1-Dioxides: From K+ATP Channel Openers to Ca++ Channel Blockers?

2002 ◽  
Vol 383 (11) ◽  
Author(s):  
R. Ouedraogo ◽  
B. Becker ◽  
S. Boverie ◽  
F. Somers ◽  
M.-H. Antoine ◽  
...  
Keyword(s):  
Channel Blockers ◽  
Ca Channel ◽  
Ca Channel Blockers

scholarly journals The Influence of Iontoforesis of Ca Channel Blockers on Pain Relief.

1992 ◽  
Vol 12 (7) ◽  
pp. 749-753
Author(s):  
Akemi MIYAGAWA ◽  
Kazuo TANIGUCHI ◽  
Akio MIZUTANI ◽  
Kazumitsu SENDAYA ◽  
Shigenori YOSHITAKE ◽  
...  
Keyword(s):  
Pain Relief ◽  
Channel Blockers ◽  
Ca Channel ◽  
Ca Channel Blockers

scholarly journals Treatment Response to Gabapentin in Neuropathic Ocular Pain Associated with Dry Eye

2020 ◽  
Vol 9 (11) ◽  
pp. 3765
Author(s):  
Hyeon-Jeong Yoon ◽  
Jonghwa Kim ◽  
Kyung Chul Yoon
Keyword(s):  
Medical History ◽  
Treatment Response ◽  
Dry Eye ◽  
Topical Treatment ◽  
Ocular Pain ◽  
Group 3 ◽  
Chemical Stimuli ◽  
Group 2 ◽  
Response Group ◽  
Group 1

Purpose: To investigate the response to gabapentin treatment in patients with dry eye (DE) accompanied by features of neuropathic ocular pain (NOP), and to analyze the differences between clinical manifestations of the groups according to treatment response. Methods: We retrospectively reviewed the records of 35 patients with DE accompanied by NOP features and obtained information on their medical history and previous ocular history. The patients underwent clinical examinations of the tear film, ocular surface, and meibomian gland and completed the Ocular Pain Assessment Survey (OPAS). One month after treatment with topical eye drops, add-on of gabapentin treatment was determined according to the Wong–Baker FACES Pain Rating Scale (WBFPS). A reduction of 2 points or more on the WBFPS was considered a positive treatment response. Enrolled patients were divided into three groups according to the treatment response: topical treatment response group (group 1, n = 11); gabapentin response group (group 2, n = 13); and gabapentin non-response group (group 3, n = 11). The medical history, clinical parameters, and OPAS scores were compared between groups. Results: The incidence of systemic comorbidities was higher in group 2 than in other groups. The corneal staining scores were lower in groups 2 and 3 than in group 1. Among the treatment response groups, group 2 showed improvements in OPAS scores of ocular pain severity, pain other than eyes, and quality of life, while group 1 showed improved OPAS scores of ocular pain severity and ocular associated factors. Group 2 exhibited lower scores of pains aggravated by mechanical and chemical stimuli than group 3. Conclusions: Gabapentin could be effective in patients who have systemic comorbidity and less pain evoked by mechanical and chemical stimuli for the treatment of DE patients with NOP, which is refractory to topical treatment.

Sign in / Sign up

Export Citation Format

Share Document